Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily make copies of Novo Nordisk’s semaglutide. The gambit boosted the telehealth firm’s stock price,

The deal will allow the telehealth company to offer the Danish drugmaker’s popular GLP-1 drug on its platform. Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk.

Key Takeaways Hims & Hers Health shares surged Tuesday as the company announced a partnership with Danish drugmaker Novo Nordisk.Hims & Hers users will have access to Novo Nordisk's Wegovy starting this week,